[go: up one dir, main page]

CU24052B1 - Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos - Google Patents

Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos

Info

Publication number
CU24052B1
CU24052B1 CU2011000088A CU20110088A CU24052B1 CU 24052 B1 CU24052 B1 CU 24052B1 CU 2011000088 A CU2011000088 A CU 2011000088A CU 20110088 A CU20110088 A CU 20110088A CU 24052 B1 CU24052 B1 CU 24052B1
Authority
CU
Cuba
Prior art keywords
anilina
cycline
sulfoximine
cdk
inhibitors
Prior art date
Application number
CU2011000088A
Other languages
English (en)
Other versions
CU20110088A7 (es
Inventor
Ulrich Lücking
Rolf Jautelat
Gerhard Siemeister
Julia Schulze
Philip Lienau
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of CU20110088A7 publication Critical patent/CU20110088A7/es
Publication of CU24052B1 publication Critical patent/CU24052B1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados de anilina-pirimidina sustituidos con sulfoximina de la fórmula (I) ESPACIO PARA LA FÓRMULA métodos de producción de los mismos y su uso como medicación para el tratamiento de diversas enfermedades.
CU2011000088A 2008-10-21 2011-04-20 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos CU24052B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08167113A EP2179991A1 (de) 2008-10-21 2008-10-21 Sulfoximinsubstituierte Anilino-Pyrimidinderivate als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
PCT/EP2009/007247 WO2010046035A1 (de) 2008-10-21 2009-10-09 Sulfoximinsubstituierte anilinopyrimidinderative als cdk-inhibitoren, deren herstellung und verwendung als arzeinmittel

Publications (2)

Publication Number Publication Date
CU20110088A7 CU20110088A7 (es) 2011-12-28
CU24052B1 true CU24052B1 (es) 2014-12-26

Family

ID=40282208

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2011000088A CU24052B1 (es) 2008-10-21 2011-04-20 Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos

Country Status (38)

Country Link
US (1) US8735412B2 (es)
EP (2) EP2179991A1 (es)
JP (1) JP5564054B2 (es)
KR (1) KR20110069115A (es)
CN (1) CN102197029B (es)
AR (1) AR074053A1 (es)
AU (1) AU2009306733C1 (es)
BR (1) BRPI0920112A2 (es)
CA (1) CA2739739C (es)
CO (1) CO6361926A2 (es)
CR (1) CR20110210A (es)
CU (1) CU24052B1 (es)
CY (1) CY1115590T1 (es)
DK (1) DK2350026T3 (es)
DO (1) DOP2011000107A (es)
EA (1) EA019230B1 (es)
EC (1) ECSP11010992A (es)
ES (1) ES2499028T3 (es)
HN (1) HN2011001019A (es)
HR (1) HRP20140830T1 (es)
IL (1) IL211713A (es)
MA (1) MA32723B1 (es)
MX (1) MX2011004238A (es)
MY (1) MY155230A (es)
NZ (1) NZ592314A (es)
PA (1) PA8846201A1 (es)
PE (1) PE20110546A1 (es)
PL (1) PL2350026T3 (es)
PT (1) PT2350026E (es)
RS (1) RS53523B1 (es)
SA (1) SA109300632B1 (es)
SI (1) SI2350026T1 (es)
TN (1) TN2011000199A1 (es)
TW (2) TWI458716B (es)
UA (1) UA103500C2 (es)
UY (1) UY32190A (es)
WO (1) WO2010046035A1 (es)
ZA (1) ZA201103727B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
DE102010014426A1 (de) * 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Verwendung neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010014427A1 (de) 2010-04-01 2011-10-06 Bayer Schering Pharma Aktiengesellschaft Kombinationen neuer pan-CDK-Inhibitoren zur Behandlung von Tumoren
DE102010046720A1 (de) * 2010-09-23 2012-03-29 Bayer Schering Pharma Aktiengesellschaft Verfahren zur Herstellung von pan-CDK-Inhibitoren der Formel (l), sowie Intermediate der Herstellung
TW201636330A (zh) * 2011-05-24 2016-10-16 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
DE102011080991A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von CCNE2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
DE102011080992A1 (de) * 2011-08-16 2013-02-21 Bayer Pharma AG Verwendung von MAD2L2 als Stratifikationsmarker bei der Behandlung von Brusttumoren mit neuen pan-CDK-Inhibitoren
US9133171B2 (en) 2011-09-16 2015-09-15 Bayer Intellectual Property Gmbh Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group
US20150051232A1 (en) * 2012-03-21 2015-02-19 Bayer Intellectual Property Gmbh Use of (rs)-s-cyclopropyl-s-(4--5-(trifluoromethyl)pyrimidin-2-yl]amino}phenyl)sulfoximide for treating specific tumours
US9884849B2 (en) * 2014-10-16 2018-02-06 Bayer Pharma Aktiengesellschaft Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group
DK3849537T3 (da) 2018-09-10 2025-01-20 Mirati Therapeutics Inc Kombinationsterapier

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4029650A1 (de) 1990-09-19 1992-03-26 Hoechst Ag 2-anilino-pyrimidine, verfahren zu ihrer herstellung, sie enthaltene mittel und ihre verwendung als fungizide
DE69832715T2 (de) 1997-07-12 2007-01-11 Cancer Research Technology Ltd. Cyclin-abhängige-kinase inhibierende purinderivate
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
ES2270612T3 (es) 1998-08-29 2007-04-01 Astrazeneca Ab Compuestos de pirimidina.
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
ATE420077T1 (de) 2001-05-29 2009-01-15 Bayer Schering Pharma Ag Cdk inhibitorische pyrimidine, deren herstellung und verwendung als arzneimittel
JP2005526765A (ja) * 2002-03-11 2005-09-08 シエーリング アクチエンゲゼルシャフト Ｃｄｋ−阻害性２−ヘテロアリール−ピリミジン類、それらの生成及び医薬としての使用
PL377795A1 (pl) 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
DE10349423A1 (de) 2003-10-16 2005-06-16 Schering Ag Sulfoximinsubstituierte Parimidine als CDK- und/oder VEGF-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP2008514571A (ja) * 2004-09-29 2008-05-08 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 細胞周期−キナーゼまたはレセプター−チロシン−キナーゼインヒビターとしての置換２−置換アニリノピリミジン類、それらの製造および薬剤としての使用
DE102005062742A1 (de) * 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Sulfoximin substituierte Pyrimidine, Verfahren zu deren Herstellung und ihre Verwendung als Arzneimittel
DE102006027156A1 (de) * 2006-06-08 2007-12-13 Bayer Schering Pharma Ag Sulfimide als Proteinkinaseinhibitoren
EP2179992A1 (de) * 2008-10-21 2010-04-28 Bayer Schering Pharma Aktiengesellschaft Sulfonsubstituierte Anlinopyrimidinderivative als CDK-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel

Also Published As

Publication number Publication date
TN2011000199A1 (en) 2012-12-17
RS53523B1 (en) 2015-02-27
AR074053A1 (es) 2010-12-22
CN102197029B (zh) 2014-05-14
HN2011001019A (es) 2013-07-01
JP2012506391A (ja) 2012-03-15
DK2350026T3 (da) 2014-09-15
MX2011004238A (es) 2011-05-23
EA019230B1 (ru) 2014-02-28
US20110294838A1 (en) 2011-12-01
TWI496774B (zh) 2015-08-21
UY32190A (es) 2010-05-31
CN102197029A (zh) 2011-09-21
EP2350026A1 (de) 2011-08-03
PT2350026E (pt) 2014-09-12
NZ592314A (en) 2013-02-22
EA201100623A1 (ru) 2011-12-30
TW201444803A (zh) 2014-12-01
AU2009306733B2 (en) 2015-11-12
EP2350026B1 (de) 2014-06-18
CO6361926A2 (es) 2012-01-20
EP2179991A1 (de) 2010-04-28
HRP20140830T1 (hr) 2014-11-21
AU2009306733A1 (en) 2010-04-29
ES2499028T3 (es) 2014-09-26
JP5564054B2 (ja) 2014-07-30
IL211713A (en) 2015-04-30
PA8846201A1 (es) 2010-05-26
BRPI0920112A2 (pt) 2015-12-22
DOP2011000107A (es) 2011-05-15
AU2009306733C1 (en) 2016-07-14
TWI458716B (zh) 2014-11-01
UA103500C2 (uk) 2013-10-25
CU20110088A7 (es) 2011-12-28
CY1115590T1 (el) 2017-01-04
MY155230A (en) 2015-09-30
CA2739739C (en) 2016-12-20
PE20110546A1 (es) 2011-08-12
PL2350026T3 (pl) 2014-11-28
WO2010046035A1 (de) 2010-04-29
US8735412B2 (en) 2014-05-27
SA109300632B1 (ar) 2013-07-04
ZA201103727B (en) 2014-11-26
CR20110210A (es) 2011-06-08
MA32723B1 (fr) 2011-10-02
KR20110069115A (ko) 2011-06-22
SI2350026T1 (sl) 2014-10-30
CA2739739A1 (en) 2010-04-29
TW201020237A (en) 2010-06-01
ECSP11010992A (es) 2011-05-31
IL211713A0 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
CU24052B1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y método de producción de los mismos
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
MX2020005498A (es) Inhibidores de cdk.
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
MX374452B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
SV2010003662A (es) Derivados de azetidina y ciclobutano como inhibidores de jak ref. x-19081
CR20120510A (es) Derivados de piperidin-4-il azetidina como inhibidores de jak1
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
ECSP11010798A (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
ECSP11011258A (es) Pirimidinas fusionadas
CR20110309A (es) Compuestos orgánicos
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
CU20140072A7 (es) Derivados de dihidro-oxazina y dihidro-pirido-oxazina
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY33486A (es) Derivados de tetrahidro-pirido-pirimidina
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
UA115868C2 (uk) Гетероциклічні сполуки, лікарські засоби, які містять зазначені сполуки, їх застосування і способи їх одержання
NI201300105A (es) Imidazopiridazinas como inhibidores de quinasa akt
UY31860A (es) Piridinas de tiazolo como inhibidoras de la adn girasa
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos

Legal Events

Date Code Title Description
FG Grant of patent